This organization files Form 990, which has no section for application policy. Its filings cannot say either way.
The latest filing we hold carries no statement about applications. That is not the same as closed: public-charity Form 990s have no field for it, and many foundations leave the section blank.
Grants paid by year
Total assets by year
Where the money went · FY2024
Form 990 splits expenses into program services, management and fundraising. The split is self-reported, and a grantmaker, a research institute and a direct-service nonprofit book the same work differently. A line the return does not carry reads "not available"; it is never counted as zero.
| Year | Form | Revenue | Expenses | Grants paid | Assets | Net assets |
|---|---|---|---|---|---|---|
| FY2024 | 990 | $436,622 | $207,197 | $142,817 | $3,970,483 | $3,846,553 |
| FY2023 | 990 | $1,709,542 | $532,571 | $275,000 | $2,454,510 | $2,414,947 |
| FY2022 | 990 | $1,214,087 | $546,181 | $431,715 | $1,163,899 | $1,053,827 |
| FY2021 | 990 | $667,347 | $464,757 | $442,500 | $385,921 | $385,921 |
| FY2020 | 990 | $262,247 | $78,916 | $75,000 | $183,331 | $183,331 |
Figures are as reported on the e-filed return, with no restatement. Fiscal years are the funder's own tax year, labelled by the calendar year the period ends in. A blank line means the return does not carry that figure; a real zero shows as $0. When an amended return replaces an original, every figure here uses the amended return. The original is not shown. Giving is what the funder actually paid out toward its charitable purpose in the year (qualifying distributions on Form 990-PF, charitable disbursements otherwise). Assets are what it holds; giving is what moves.
Recipient focus areas
Where recipients are
Based on the 100% of grant rows we could match to an organization record. The rest stay as reported. The IRS assigns the NTEE category when it grants exemption. It often reflects the original filing, not today's giving.
| Recipient | Purpose | Amount | Year | Source |
|---|---|---|---|---|
| THE CLEVELAND CLINIC FOUNDATIONCLEVELAND, OH | PRE-CLINICAL VALIDATION STUDIES FOR PERSONALIZED MRNA VACCINE - DR. TIMOTHY CHAN AND COMPENSATION IN SUPPORT OF PRINCIPAL INVESTIGATOR IN EWS CLINICAL TRIAL | $275,000 | 2022 | |
Recipients are shown as the funder wrote them on the return. A recipient with a link was matched to an organization record; the rest stay as reported and are never guessed.
| Name | Title | Hours / week | Compensation |
|---|---|---|---|
| Emily Mcfadden | SECRETARY | 20.00 | $9,000 |
| Leah Christianson | TREASURER | 20.00 | $8,280 |
| Piero Spada | CO-FOUNDER / PRESIDENT | 10.00 | $0 |
| Maggie Spada | CO-FOUNDER / BOARD MEMBER |
From the officer list on the latest e-filed return. Compensation is as reported there; a blank means the return carries no figure.
| CLEVELAND CLINIC FOUNDATIONCLEVELAND, OH |
| PRE-CLINICAL STUDIES FOR MRNA VACCINE |
| $275,000 |
| 2023 |
| DANA-FABER CANCER INSTITUTEBROOKLINE, MA | EWING SARCOMA CTDNA LIQUID BIOPSY STUDY AS A SURVEILLANCE MECHANISM DURING REMISSION BY DR. CROMPTON AND DR. SHULMAN | $150,000 | 2021 |
| BEAT CHILDHOOD CANCERTAMPA, FL | INITIAL SUPPORT FOR IN:FORMATION EWING SARCOMA PRECISION MEDICINE PROGRAM SPEARHEADED BY DR. SHOLLER | $100,000 | 2021 |
| THE CLEVELAND CLINIC FOUNDATIONCLEVELAND, OH | SBRT AND IMMUNOTHERAPY STUDY FOR EWING SARCOMA LED BY DR. ERIN MURPHY AND DR. PETE ANDERSON | $100,000 | 2021 |
| CHILDREN'S CANCER THERAPYBEAVERTON, OR | RESEARCH | $75,000 | 2020 |
| BEAT CHILDHOOD CANCERTAMPA, FL | IN:FORMATION EWING SARCOMA PRECISION MEDICINE PROGRAM SPEARHEADED BY DR. SHOLLER | $65,000 | 2022 |
| GEORGETOWN UNIVERSITYWASHINGTON, DC | PRODUCTION OF EWS-FLI1 PROTEIN ACCORDING TO SPECIFICATION REQUIREMENTS (DR. AYKUT REN) | $55,000 | 2021 |
| MEMORIAL SLOAN KETTERING CANCER CENTERNEW YORK, NY | PHASE II STUDY OF THE ORAL CHK1 INHIBITOR / LOW-DOSE GEMCITABINE IN EWS PATIENTS | $50,000 | 2022 |
| UNIVERSITY OF VIRGINIACHARLOTTESVILLE, VA | RESEARCH AND PROVIDE DATA FOR DEVELOPMENT OF INHIBITORS | $42,817 | 2024 |
| CHILDREN'S CANCER THERAPY DEVELOPMENT INSTITUTEBEAVERTON, OR | THIRD INSTALLMENT TO SISU PROJECT, PRE-CLINICAL RESEARCH FOR A VIABLE MAINTENANCE THERAPY FOR EWS | $37,500 | 2022 |
| CHILDREN'S CANCER THERAPYBEAVERTON, OR | SECOND INSTALLMENT TO SISU PROJECT, PRE-CLINICAL RESEARCH FOR A VIABLE MAINTENANCE THERAPY FOR EWING SARCOMA (DR. KELLER) | $37,500 | 2021 |
| 10.00 |
| $0 |
| Mike Burton | BOARD MEMBER | 1.00 | $0 |
| Tim Frank | BOARD MEMBER | 1.00 | $0 |
| Melissa Oberst | BOARD MEMBER | 1.00 | $0 |
Nearest by size, location and giving pattern in the database. Geography weighs heavily. Treat it as a starting list, not a ranking of fit.
Form 990 · FY2024 · period ending Sep 30, 2024IRS bulk XML
Filing id 202531339349303348
Form 990 · FY2023 · period ending Sep 30, 2023IRS bulk XML
Filing id 202402289349301655
Form 990 · FY2022 · period ending Sep 30, 2022
Filing id 202302279349304865
Form 990 · FY2021 · period ending Sep 30, 2021
Filing id 202242249349302314
Form 990 · FY2020 · period ending Sep 30, 2020
Filing id 202102169349300025
IRS filings are the source for every fact on this page. Nothing a model writes is ever a source; it can only point at a row here.